Kalydeco (ivacaftor)

pCPA File Number: 21250
Negotiation Status:
Active Negotiation
Indication(s):
cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation
Sponsor/Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable